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Abstract
Cancer-associated fibroblasts enhance cancer progression when activated by tumor cells through
mechanisms not yet fully understood. Blocking mammary tumor cell-derived lysyl oxidase-like 2
(LOXL2) significantly inhibited mammary tumor cell invasion and metastasis in transgenic and
orthotopic mouse models. Here we discovered that tumor-derived LOXL2 directly activated
stromal fibroblasts in the tumor microenvironment. Genetic manipulation or antibody inhibition of
LOXL2 in orthotopically grown mammary tumors reduced the expression of α-smooth muscle
actin (α-SMA). Using a marker for reticular fibroblasts, it was determined that expression of α-
SMA was localized to fibroblasts recruited from the host tissue. This marker also revealed that the
matrix present in tumors with reduced levels of LOXL2 was more scattered compared to control
tumors which exhibited matrices with dense, parallel alignments. Importantly, in vitro assays
revealed that tumor-derived LOXL2 and a recombinant LOXL2 protein induced fibroblast
branching on collagen matrices, as well as increased fibroblast-mediated collagen contraction and
invasion of fibroblasts through extracellular matrix (ECM). Moreover, LOXL2 induced the
expression of α-SMA in fibroblasts grown on collagen matrices. Mechanistically, it was
determined that LOXL2 activated fibroblasts through integrin-mediated FAK activation. These
results indicate that inhibition of LOXL2 in tumors not only reduces tumor cell invasion but also
attenuates the activation of host cells in the tumor microenvironment.
Implications: These findings reveal new insight into the mechanisms of fibroblast activation, a
novel function of LOXL2, and further highlight the importance of generating LOXL2-targeted
therapies for the prevention of tumor progression and metastasis.
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INTRODUCTION
Fibroblasts are the principal cell type of normal connective tissues. They are embedded
within the fibrillar extracellular matrix (ECM) and are primarily responsible for its
deposition and remodeling, as well as synthesizing components of the basement membrane
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(1, 2). Not only do fibroblasts play a crucial role in the maintenance of normal ECM
homeostasis, they are also integral to wound healing, organ fibrosis (2, 3) and tumor
progression (reviewed in (4)). Cancer associated fibroblasts (CAFs), together with
endothelial cells, pericytes, smooth muscle cells, immune cells, growth factors, cytokines,
and a specialized ECM, make up the tumor microenvironment (5). CAFs are themselves a
heterogeneous population of cells with a varying number being referred to as activated
fibroblasts or myofibroblasts due to expression of α-smooth muscle actin (α-SMA) (6-8).
Importantly, CAFs appear to harbor unique cancer-promoting properties that “normal”
fibroblasts lack. It has been shown that the growth of breast, prostate, pancreas and skin
cancer cells in mice is significantly enhanced when they are co-implanted with α-SMA-
positive CAFs isolated from solid tumors (9-14). Even non-tumorigenic prostate epithelial
cells could be induced to form tumors in immunocompromised mice when mixed with CAFs
(15).
The tumor-stroma crosstalk has been shown to play a fundamental role in tumor
progression. Factors secreted from the tumor cells activate local fibroblasts, which in turn
secrete increased levels of growth factors, chemokines, ECM proteins and matrix
remodeling enzymes to modify the tumor microenvironment and promote proliferation,
survival, invasion and metastasis of the tumor cells (5, 16-18). Fibroblasts sense changes in
their microenvironment through integrins (19), and form focal adhesion complexes with
intracellular molecules that engage the cytoplasmic tyrosine kinases, focal adhesion kinase
(FAK) and Src, to activate multiple signaling pathways (20-22). FAK is also responsible for
relaying signals from growth factors and cytokines, such as TGFβ, leading to the expression
of α-SMA and concurrent activation of fibroblasts (23).
Despite their clear role in promoting metastasis, the tumor-fibroblast interactions needed for
fibroblast activation are largely unknown. We have previously shown that blocking
mammary tumor cell-derived lysyl oxidase-like 2 (LOXL2) significantly inhibits mammary
tumor cell invasion and metastasis in transgenic and orthotopic mouse models (24). In this
study we investigate the role of LOXL2 in the tumor stroma and demonstrate that LOXL2
mediates fibroblast activation through integrin engagement and FAK signaling.
MATERIALS AND METHODS
Generation of cell lines
C57Bl/6 fibroblasts were a kind gift from Joni Mäki and Johanna Myllyharju. These were
isolated from the dermis of C57Black6 mice. 3T3 fibroblasts were obtained from the ATCC.
Cells were grown in GIBCO®DMEM media (Invitrogen) supplemented with 10% fetal calf
serum (FCS) at 37°C and 5% CO2.
4T1 mouse breast cancer cells were a kind gift from Fred Miller (25) and had been
authenticated using short tandem repeat (STR) analysis within the last 6 months. Cells were
grown in DMEM supplemented with 10% FCS at 37°C and 5% CO2. Cells were infected
with lentiviruses expressing short hairpin RNA (shRNA) libraries specific to mouse Loxl2
(TRC-Mm1.0; Open Biosystems).
Preparation of conditioned media
Growth media was removed from cells at about 75% confluency in T75 flasks, cells were
washed thoroughly and incubated in 10 mL of serum-free DMEM for 24 hours at 37°C and
5% CO2. Conditioned media (CM) was collected from cells and filtered through 45 μm
filters (Millipore).
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Fibroblast growth assays
6-well plates were prepared by adding 1 mL of collagen mix (50% 1 × DMEM, 1.5mg rat
tail collagen I (BD Biosciences) with pH adjusted by addition of 5M NaOH and made up to
1mL with PBS) to each well and allowing it to set at 37°C. Fibroblasts were plated on the
collagen at a density of 2 × 105 cells per well in normal growth media and allowed to settle
overnight. Growth media was removed from the fibroblasts and replaced with serum-free
media (SFM) or CM from 4T1 breast cancer cells. Cells were also incubated in SFM
containing 10ng/ml TGFβ (Sigma) or 30μM recombinant LOXL2 protein. Specific
antibodies were added at various concentrations: LOXL2 (N-15; Santa Cruz Biotechnology
Inc.; 12μg/ml), β1 integrin (Millipore; 10μg/ml), α5β1 integrin (Abcam), or β3 integrin
(Santa Cruz Biotechnology Inc.; 20μg/ml). Specific inhibitors to Src (Src inhibitor (26);
1:100) or FAK (FAK inhibitor 14 (27, 28); 1:50) were also used. Control Armenian hamster
IgG (Santa Cruz Biotechnology Inc.) and sodium citrate buffer were added to SFM as
controls for the antibodies and inhibitors respectively.
Invasion assays
Transwell invasion assays were carried out as previously described (29). Briefly, 2.5 × 104
fibroblasts were seeded in each Matrigel-coated transwell and 4T1 conditioned media (CM)
placed in the bottom wells to act as a chemoattractant. Goat isotype control (Sigma) or
LOXL2-specific (N-15; Santa Cruz Biotechnology Inc) antibodies were added to either the
fibroblasts or the CM. In other experiments SFM containing 30μM recombinant human
LOXL2 was placed in the bottom wells to act as chemoattractant. SFM alone was used as a
control. Parallel assays were carried out in uncoated control transwell inserts to assess cell
migration in the absence of ECM.
Collagen contraction assays
2×105 fibroblasts were suspended in a collagen mixture (100μl of cells in normal growth
media mixed with 200μl of collagen mix as described above for growth assays) per well of
24-well plates pre-coated with 0.5% BSA and allowed to set at 37°C. Gels were incubated in
normal growth media for 24 hours. Growth media was removed and SFM or 4T1 CM
containing specific antibodies or recombinant proteins at concentrations mentioned
previously was added to the wells and gels released. Gels were photographed at various
time-points and ImageJ used to measure gel area and assess contraction.
Western blotting
Lysates were prepared from cell pellets in 1% NP40 lysis buffer. Proteins from lysates were
separated on NuPAGE® Novex® Bis-Tris 10% gels (Invitrogen). Gels were transferred to
PVDF membranes (Millipore) and probed with antibodies specific to beta-actin, α-SMA, p-
FAK (Y397) (Abcam), Akt (9272), p-Akt (S473), (Cell signaling), FAK (610087) (BD
Biosciences).,
ELISA
ELISA plates were incubated with CM overnight, washed and blocked before incubating
with antibody specific to LOXL2 (N-15, Santa Cruz; 1:100), washing and incubating with
goat secondary antibody (Santa Cruz). Wells were washed and incubated with europium
labelled antibody before developing with DELFIA enhancement solution (PerkinElmer,
Inc.). Plates were read at 615nm on a SpectroMax 5 plate reader (Molecular Devices).
LOXL2 activity assay
Fluorescence-based enzymatic activity assays were carried out as previously described (24).
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MTS assays
Cells were plated in triplicate in 96-well plates, either on a layer of 50% collagen or within a
layer of 33% collagen (as above for growth and contraction assays), and allowed to set at
37°C. SFM alone or containing TGFβ or recombinant LOXL2 protein was added to the
wells and cell proliferation assay performed on days 0, 1, 2, 3. For measurements, 20 μl of
CellTiter 96® AQueous One Solution reagent (Promega) was directly added to media in
culture wells, plates incubated for 2 hr at 37°C, then absorbance measured at 490 nm using a
SpectroMax5 plate reader (Molecular Devices).
Quantitative real-time PCR
Total RNA was isolated from cell pellets using RNeasy Mini Kits (Qiagen). DNase
treatment and cDNA synthesis were performed using QuantiTect Reverse Transcription Kits
(Qiagen). Quantitative real-time PCRs for mouse beta-actin, Loxl2 and acta2 were
performed using TaqMan® Gene Expression Assays (Applied Biosystems). Quantitative
real-time PCR for mouse SDF1 and FN was performed using SYBR green mix (Promega)
and the following primers:
FN: AGGCATAAGGTTCGGGAAGAGGT (forward)
GCAGTTGTCACAGCGCCAGCC (reverse)
SDF1: CTTCATCCCCATTCTCCT (forward)
GACTCTGCTCTGGTGGAAGG (reverse)
In vivo assays
For orthotopic models, control and shLOXL2 4T1 cells (1×105) were injected into the fourth
mammary fat pad of 6-8 week old female syngeneic Balb/c (Harlan) mice. All experiments
were approved by the Home Office and performed following UKCCCR Guidelines for the
welfare and use of animals in cancer research. Treated mice received twice weekly
intraperitoneal injections of anti-LOXL2 antibody (N-15; Santa Cruz Biotechnology Inc.) or
IgG from goat serum (Sigma) at 0.5mg/kg for 4 weeks. Mice were culled when tumors
reached maximum size. Tumors were removed and either fixed in 4% paraformaldehyde or
frozen in optimal cutting temperature (OCT) compound (Tissue-Tek®).
Immunohistochemistry/Immunofluorescence
Paraffin embedded tissue sections were deparaffinized, rehydrated and incubated with 3%
hydrogen peroxidase in methanol for 15 minutes to quench endogenous peroxidase activity.
Antigen retrieval was carried out in a target retrieval solution (Dako) at 95°C for 15 minutes.
Non-specific binding was blocked by incubation with 5% goat serum for 1 hour. Primary
antibodies were applied overnight at 4°C, and biotinylated secondary antibodies for 45
minutes at room temperature, followed by a final 30 minute incubation with streptavidin-
biotin peroxidase solution. Visualization was carried out using 3,3′-diaminobenzine (DAB)
and counterstaining using Mayer’s haemalum. Flash frozen tissue sections were fixed in
methanol and stained using Alexa Fluor® secondary antibodies (Molecular Probes,
Invitrogen). Methods as previously described (29, 30). Antibodies are described above plus
an antibody that detects the ER-TR7 antigen (Santa Cruz). Samples were visualized using an
Olympus BX51 and a 10x or 20x magnification lens. Images were analyzed using Cell D
software (Olympus). Brightness and contrast were adjusted equally in all images presented.
Statistical Analysis
Data was analyzed using the Student t-test unless otherwise stated, and considered
significant when the p value was <0.05. All statistical tests were two-sided. Bar graphs
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represent the mean and standard error across multiple independent experimental repeats
unless otherwise stated. Statistical significance representations: *p<0.05, **p<0.01,
***p<0.001.
RESULTS
Inhibition of LOXL2 reduces α-SMA expression in 4T1 orthotopic tumors
We have previously shown that LOXL2 expression is clinically correlated with metastasis
and that 4T1 mouse mammary cancer cells metastasize in a LOXL2-dependent manner in
vivo (24). We sought to better understand how tumor-derived LOXL2 could enhance tumor
progression, with a focus on fibroblast activation. We first manipulated LOXL2 expression
in 4T1 cells. 4T1 cells were infected with a scrambled control or mouse LOXL2-specific
shRNA viruses to generate knockdown (4T1 shLOXL2) and control (4T1 control) cell lines.
The shLOXL2 cell lines had significantly decreased expression of LOXL2 mRNA and
protein compared with controls (24). ELISA and activity assays were carried out to further
confirm that shLOXL2 cells expressed less LOXL2 protein and had lower LOXL2 activity
(Supplementary Figures 1A + B, respectively).
To assess the role of tumor-derived LOXL2 on host stromal cells, control and shLOXL2
cells were implanted into the mammary fat pad of Balb/c mice. 4T1 wild-type (4T1 wt) cells
were also implanted into Balb/c mice and these mice received twice weekly doses of either a
control IgG or a LOXL2-specific targeting antibody (24), to block secreted LOXL2
function. Tumors were harvested when they reached maximum size. Tumor sections were
stained with antibodies specific for α-SMA, a marker of fibroblast activation. Inhibition of
LOXL2 both by genetic means as well as antibody means led to a reduction in α-SMA-
positive activated fibroblasts in the tumors (Figure 1A).
ER-TR7 is a marker for reticular fibroblasts and is also an antigen present on the ECM
secreted by these fibroblasts, therefore using an antibody that detects the ER-TR7 antigen
provides a means to identify fibroblasts and also visualize the fibrillar mesh-like ECM
structure present in a tissue (31). To analyze the activated fibroblasts embedded in the ECM
of the 4T1 tumors, sections were co-stained with antibodies specific for ER-TR7 and α-
SMA. Control tumors contained many cells expressing α-SMA (red) embedded within an
ECM matrix consisting of dense fibres lined up in a parallel fashion (green) (Figure 1B, left
panels). In comparison, shLOXL2 tumors expressed very low levels of α-SMA and
exhibited a scattered ECM structure (Figure 1B, right panels). Expression of α-SMA (red)
was also analyzed by immunofluorescence in tumor sections taken from mice treated with
control IgG or LOXL2-specific antibody (Figure 1C). Quantification of α-SMA cells in
these tumor sections confirmed that inhibition of LOXL2 either genetically or by using a
LOXL2-specific antibody resulted in significantly fewer α-SMA-positive cells (P < 0.0001
and P = 0.008, respectively; Figure 1D). 4T1 shLOXL2 tumors also possessed significantly
lower levels of ER-TR7 staining compared to 4T1 control tumours (P = 0.003;
Supplementary Figure 1C). These findings suggest that LOXL2 facilitates fibroblast
activation and production of a strong fibrous ECM structure in 4T1 tumors, both of which
are known to enhance tumor cell invasion and metastasis (32-36).
Inhibition of tumor-secreted LOXL2 reduces the branching of fibroblasts grown on
collagen
Following the observation that 4T1 tumors expressing high levels of LOXL2 exhibited
extensive α-SMA expression compared with 4T1 shLOXL2 tumors, we sought to determine
whether LOXL2 could drive fibroblast activation. Not all CAFs express α-SMA and once
they do begin to express α-SMA they are not truly functional myofibroblasts until they have
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gained contractile properties by incorporating α-SMA into stress fibres (37), therefore, we
used a number of in vitro models to assay LOXL2-mediated phenotypic changes in the
fibroblasts. Initially, the morphology of fibroblasts grown on collagen matrices was
assessed. Conditioned media (CM) from 4T1 cells was used as a source of tumor secreted
factors, including high levels of LOXL2, in the following experiments. Immortalized mouse
dermal fibroblasts, referred to simply as fibroblasts from hereon, plated on a layer of
collagen initially formed round structures in the presence of serum-free media (SFM) and
started to develop a branched phenotype after 48 hours. Fibroblasts were plated on top of a
layer of collagen in normal growth media and allowed to adhere for 24 hours. The cells were
then washed with SFM and incubated for 48 hours in 4T1 CM in the presence or absence of
a LOXL2-specific targeting antibody. A goat isotype IgG was used as a control. Cells in
adjacent wells were incubated with SFM alone. The fibroblasts formed branched structures
within 24 hours in the presence of 4T1 CM (Figure 2A, centre panel). Inhibition of LOXL2
using a LOXL2-specific antibody dramatically reduced the ability of the fibroblasts to form
branched structures (Figure 2A, right panel), suggesting tumor-secreted LOXL2 can activate
fibroblasts in culture.
Inhibition of tumor-secreted LOXL2 reduces the ability of fibroblasts to invade through
ECM
To investigate if tumor-secreted LOXL2 could influence fibroblast invasion we performed
transwell invasion assays. Fibroblasts were plated on top of a layer of recombinant basement
membrane (Matrigel) in transwell inserts. 4T1 CM was used as the ‘chemoattractant’ and
SFM as a control. Uncoated (i.e. ECM-free) control transwell inserts were used to assess cell
migration. The LOXL2-targeting antibody was used to inhibit fibroblast- or tumor-derived
LOXL2 by adding it to either the fibroblasts or the CM chemoattractant, respectively. A
goat isotype IgG was added to adjacent control wells. After incubation for 24 hours the
number of fibroblasts that had invaded through the ECM towards the CM was quantified.
Limited invasion of fibroblasts was observed when SFM was used as a control
chemoattractant. In contrast, the fibroblasts became highly invasive when CM was used as a
chemoattractant (P < 0.0001; Figure 2B). Inhibition of fibroblast- or tumor-derived LOXL2
significantly reduced the ability of the fibroblasts to invade through the ECM towards CM
(P < 0.0001; Figure 2B). Importantly, inhibition of LOXL2 had no effect on non-invasive
cell migration in the control transwell inserts (Figure 2C). These findings suggest that
LOXL2 secreted from the fibroblasts as well as the tumor cells is required to facilitate
fibroblast invasion through ECM.
LOXL2 is required for fibroblast-mediated collagen contraction
When surrounded by matrix in the presence of tumour-secreted factors, fibroblast-matrix
adhesions increase as a result of fibroblast activation, leading to contraction of the collagen
matrices. We therefore investigated the effect of tumor-secreted LOXL2 on fibroblast-
mediated collagen contraction. Fibroblasts were suspended in collagen matrices and
incubated in 4T1 CM in the presence or absence of a LOXL2-targeting antibody. A goat
isotype IgG was used as a control. Addition of the CM induced the fibroblasts to contract the
collagen gels by 63.43 ± 4.10% over 96 hours (Figure 2D + E). In contrast, fibroblasts
suspended in collagen gels exposed to CM and a LOXL2-specific antibody were only able
to induce 41.28 ± 4.91% contraction over the same period, similar to the rate of contraction
observed for the control gels, where fibroblasts were suspended in collagen incubated in
SFM alone (Figure 2D + E). Quantitative analysis revealed that the LOXL2-specific
antibody significantly inhibited contraction at 24, 48 and 96 hours (P = 0.0018, 0.0089 and
0.0061, respectively; Figure 2E). To confirm that LOXL2 facilitates fibroblast branching on
collagen and contraction of collagen these assays were performed with 4T1 shLOXL2 CM.
Similarly to fibroblasts incubated with 4T1 CM in the presence of a LOXL2-specific
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antibody, fibroblasts incubated with 4T1 shLOXL2 CM formed fewer branches on collagen
and had decreased collagen contraction ability (Supplementary Figure 2).
Recombinant LOXL2 protein induces fibroblast branching, contraction and invasion
To confirm that LOXL2 in the CM was driving fibroblast activation we assessed the
response of fibroblasts to recombinant LOXL2 protein (rLOXL2). TGFβ is the most potent
myofibrogenic growth factor in wound healing and fibrosis (38-40) and provided a positive
control for fibroblast activation. Fibroblasts formed more extensive branched structures after
24 hours in the presence of TGFβ compared to SFM alone (Figure 3A). Importantly,
addition of rLOXL2 induced the fibroblasts to form extensive branched structures within 24
hours, comparable to the rate of branching observed in response to TGFβ, suggesting that
LOXL2 alone is able to activate fibroblasts (Figure 3A, right panel).
Recombinant LOXL2 was also able to induce 57.34 ± 3.28% fibroblast-mediated collagen
contraction over 96 hours compared with 41.52 ± 3.32% contraction observed for control
fibroblasts incubated in SFM alone (Figure 3B + C). Quantitative analysis revealed that
rLOXL2 significantly enhanced contraction above what was observed in SFM alone at 24,
48 and 96 hours (P = 0.035, <0.0001 and 0.0069, respectively; Figure 3C).
To determine whether rLOXL2 could increase fibroblast invasion directly, transwell
invasion assays were carried out. Significantly increased invasion through ECM was
observed when rLOXL2 was provided as a chemoattractant (P = 0.0016; Figure 3D). Of
note, rLOXL2 was unable to induce fibroblast migration through uncoated control
membranes (Figure 3E). These findings further support the direct effects of LOXL2 on
fibroblast activation as measured by increased branching on collagen matrices, collagen
contraction and invasion.
Fibroblasts exposed to rLOXL2 express increased α-SMA
To determine whether fibroblasts incubated with rLOXL2 were indeed activated at a
molecular level, fibroblasts were grown on collagen and harvested for protein and RNA
analysis 48 hours after the addition of rLOXL2. Western blotting revealed that exogenous
LOXL2 induced the expression of α-SMA to similar levels observed in fibroblasts incubated
with TGFβ (Figure 4A). Quantitative real time-PCR (QRT-PCR) analysis confirmed a 2.58-
fold (± 0.20) increase in the expression of the gene encoding α-SMA (acta2) following
incubation with rLOXL2 (P < 0.0001; Figure 4B). These results support a role for LOXL2 in
directly activating fibroblasts.
Recombinant LOXL2 does not induce fibroblast proliferation
To confirm that LOXL2-mediated phenotypic changes were not due to altered proliferation,
we carried out MTS assays. Fibroblasts were plated on a layer of collagen, to mimic
branching assays, or mixed within a collagen matrix, to mimic collagen contraction assays,
and stimulated with TGFβ or rLOXL2 for 3 days. Cell growth in separate wells was
measured each day. No significant differences in proliferation of fibroblasts plated either on
collagen or in collagen after incubation with rLOXL2 were observed (Figure 4C + D),
supporting the effects of LOXL2 on fibroblast phenotype being due to fibroblast activation
alone. Interestingly, addition of TGFβ significantly decreased the proliferation of fibroblasts
grown on collagen (P = 0.0013 and 0.042 on day 2 and 3, respectively; Figure 4C) and
increased the proliferation of fibroblasts grown in collagen (P = 0.011 and 0.0062 on day 1
and 2, respectively; Figure 4D). This highlights the complexity of TGFβ action on cell
proliferation and differentiation and suggests that LOXL2 may activate fibroblasts in a
TGFβ-independent manner.
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Fibroblasts exposed to rLOXL2 exhibit increased expression of SDF1 and fibronectin
Activated CAFs secrete elevated levels of extracellular matrix proteins and tumor-promoting
factors such as fibronectin (FN) and stromal cell-derived factor 1 (SDF1) (4, 12, 13). To
determine whether fibroblasts activated in the presence of exogenous LOXL2 express more
FN and SDF1, cells were plated on collagen, stimulated with rLOXL2 for 48 hours and gene
expression assessed by QRT-PCR. Unstimulated fibroblasts provided a control. Fibroblasts
stimulated with rLOXL2 exhibited a 19.00-fold (± 3.51) increase in the expression of SDF1
(P = 0.0006; Figure 4E, left panel). In addition, rLOXL2-stimulated fibroblasts exhibited a
significant but less dramatic 1.69-fold (± 0.20) increase in the expression of FN (P = 0.0037;
Figure 4E, centre panel). Interestingly, these fibroblasts also expressed 1.75-fold (± 0.11)
increased levels of LOXL2 (P < 0.0001; Figure 4E, right panel), suggesting a positive feed
forward loop has been established which maintains high levels of secreted LOXL2 in the
tumor microenvironment.
LOXL2 mediates fibroblast activation through β3 integrins
Our findings suggested a role for secreted LOXL2 in fibroblast activation. One method by
which fibroblasts respond to external signals is through integrins (41) and the most common
integrins found in focal adhesions contain the β1 and β3 subunits (42, 43). To determine
whether these integrin subunits mediate fibroblast activation in response to exogenous
LOXL2 we used β1 and β3 function-blocking antibodies. Fibroblasts were plated on
collagen matrices and allowed to adhere for 24 hours. Cells were then washed and incubated
with rLOXL2 in the presence or absence of integrin-specific blocking antibodies. A hamster
isotype IgG was used as a control. LOXL2-mediated formation of branches was reduced in
the presence of integrin β3-specific antibody but not in the presence of integrin β1-specific
antibody (Figure 5A). To confirm these findings, cells were harvested for western blotting
analysis. Consistent with the phenotypic studies, integrin β3-specific antibody but not
integrin β1-specific antibody could block LOXL2-mediated activation of fibroblasts as
determined by the expression of α-SMA (Figure 5B).
LOXL2 activates fibroblasts through FAK and Akt signaling
Focal adhesion kinase (FAK) is a critical component of focal adhesions that associates with
integrins and relays signals from extracellular stimuli (20, 44, 45). We investigated whether
LOXL2-driven fibroblast activation was mediated via FAK phosphorylation. Firstly,
fibroblasts plated on collagen matrices were incubated with rLOXL2 in the presence or
absence of integrin-specific blocking antibodies. Western blot analysis revealed that
phosphorylation of FAK was increased in cells exposed to rLOXL2 (Figure 5C). Incubation
with an integrin β3-specific antibody reduced FAK phosphorylation as well as
phosphorylation of Akt downstream of FAK (Figure 5C). This inhibition was specific for
integrin β3, as integrin β1-blocking antibodies did not reduce FAK or Akt activation
mediated by rLOXL2 (Figure 5C). Indeed, blocking with the integrin β1-blocking antibody
appeared to increase phosphorylation of Akt. Therefore, we tested another integrin β1-
blocking antibody, which targets integrin α5β1. In addition, we tested all the antibodies on
3T3 fibroblasts to confirm the previous results were not just a characteristic of C57Bl/6
fibroblasts. Once again, inhibition of rLOXL2-mediated activation of FAK, Akt and α-SMA
in fibroblasts grown on collagen was specific for integrin β3 and was not affected by
blocking integrin β1 (Supplementary Figure 3A). Furthermore, neither of the two integrin
β1-blocking antibodies was able to inhibit rLOXL2-mediated collagen contraction by 3T3
fibroblasts, whereas a reduction in collagen contraction was observed following treatment
with integrin β3-blocking antibody (Supplementary Figure 3B).
To confirm that LOXL2 mediates activation of fibroblasts through FAK signaling, a FAK
inhibitor (FAKI) was added to fibroblasts growing on collagen in the presence of rLOXL2.
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Phosphorylation of FAK was reduced following incubation with the FAKI and this led to
decreased Akt phosphorylation and reduced expression of α-SMA (Figure 5D). We also
tested the involvement of SRC, another important component of focal adhesion complexes,
by adding a SRC inhibitor (SRCI) to fibroblasts incubated with rLOXL2. This did not result
in decreased phosphorylation of FAK (when compared to total FAK levels) or Akt, nor was
a decrease in the expression of α-SMA observed (Figure 5D), demonstrating that LOXL2
activates fibroblasts specifically through engaging the FAK/Akt signaling pathway.
DISCUSSION
The influence of the tumor microenvironment on the proliferation, invasion and metastatic
potential of the tumor cells is now widely appreciated, however, the underlying molecular
mechanisms have remained unclear. In particular, the tumor-promoting ability of α-SMA-
positive CAFs, the myofibroblasts, has been demonstrated in breast, prostate, pancreatic and
skin cancer mouse models (9-14). Following the observation that 4T1 tumors expressing
very high levels of LOXL2 exhibited extensive α-SMA expression compared with 4T1
shLOXL2 tumors, we sought to determine whether LOXL2 could facilitate fibroblast
activation and hence play a role in formation of the myofibroblast population of CAFs
present in the tumor microenvironment. By assaying for α-SMA expression as well as
phenotypic changes we were able to investigate the role of LOXL2 in fibroblast activation.
Fibroblasts exposed to tumor-derived LOXL2 or recombinant LOXL2 protein exhibited
increased rates of branching on collagen matrices and increased contraction of collagen. In
addition, tumor-derived LOXL2 as well as rLOXL2 behaved as chemoattractants in
transwell assays, inducing fibroblasts to invade through ECM. Finally, fibroblasts incubated
with rLOXL2 expressed elevated levels of α-SMA, SDF1, FN and LOXL2, further
confirming the activated state of these cells. We hypothesized that exogenous LOXL2 was
inducing fibroblast activation through engaging integrins and activating components of focal
adhesion complexes. Indeed, rLOXL2 induced α-SMA expression in the fibroblasts through
β3 integrin, FAK and Akt activation. In contrast to the decreased Akt activation seen in the
presence of integrin β3-blocking antibodies, we noted a slight increase in Akt activation
following inhibition of integrin β1 with two separate blocking antibodies. The reason for this
apparent increased Akt activation is unknown and will be subject to future investigations.
Finally, the fibroblasts used in all of these studies were of C57Bl/6 origin. We validated
many of the results in 3T3/Swiss fibroblasts demonstrating that LOXL2-mediated fibroblast
activation was not strain specific.
LOXL2 was first identified due to its overexpression in normal senescent human fibroblasts
(46). Interestingly, it has been shown that many genes overexpressed in senescent fibroblasts
are also upregulated in CAFs (47). Moreover, LOXL2 belongs to a gene expression
signature in fibroblasts that is upregulated in response to serum and has the ability to predict
cancer progression (48) and outcome in patients with breast cancer (49). Together with the
data we have presented here it is clear that LOXL2 plays an important role in fibroblasts and
their activation in the tumor microenvironment.
We have previously shown that inhibiting LOXL2 in mammary cancer cells reduces tumor
cell invasion and metastasis, without reducing primary tumor growth (24). The data we have
presented here suggest that the decreased metastasis observed following LOXL2 inhibition
is due not only to decreased invasion of the tumor cells themselves but also to reduced
fibroblast activation in the tumor stroma. Importantly, we have additionally shown that
activated fibroblasts then express more LOXL2, driving a feed-forward loop to further
enhance cancer progression. Hence, treatment of the mice with LOXL2-specific inhibitors
will inhibit fibroblast-derived LOXL2 both directly and indirectly. Therefore, the functional
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significance of inhibiting LOXL2-mediated activation of fibroblasts is the reduction of
tumor cell invasion and metastasis rather than decreased growth of the primary tumor.
In summary, our findings uncover a novel mechanism of fibroblast activation, a novel
function for LOXL2, and strongly support the targeting of tumor-derived LOXL2 to prevent
cancer progression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Inhibition of LOXL2 in vivo decreases fibroblast activation and production of a dense
ECM structure
(A) Immunofluorescent images of 4T1 control and shLOXL2 tumor sections as well as
sections from wild-type tumors (4T1 wt) grown in mice treated with control antibody (cont
IgG) or LOXL2-specific antibody (LOXL2 Ab) stained with an α-SMA-specific antibody
and counterstained with haematoxylin. n = 8 and 8 for mice harboring 4T1 control and
shLOXL2 tumors respectively. n = 3 for mice harboring 4T1 wt tumors treated with control
IgG and LOXL2 antibody. 2-3 sections were stained for each tumour per mouse. Scale bar,
200μm. (B) Immunofluorescent images of 4T1 control and shLOXL2 tumor sections stained
with antibodies to detect α-SMA (red) and the ER-TR7 antigen (green). Sections were
counterstained with dapi (blue). n = 4 and 7 for mice harboring 4T1 control and shLOXL2
tumors respectively. 2-3 sections were stained for each tumour per mouse. Scale bar,
100μm. (C) Immunofluorescent images of 4T1 wt tumor sections taken from mice treated
with control antibody (cont IgG) or LOXL2-specific antibody (LOXL2 Ab) stained with an
α-SMA-specific antibody (red) and counterstained with dapi (blue). n = 3 for each
treatment. Scale bar, 50μm. (D) Quantification of α-SMA positive cells in 4T1 control and
shLOXL2 tumors (n = 4 and 7 respectively) as well as 4T1 wt tumors treated with control
IgG or LOXL2 antibody (n = 3). **P < 0.01 and ***P < 0.001.
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Figure 2. Tumor-derived LOXL2 facilitates fibroblast branching on collagen, fibroblast invasion
and collagen contraction
(A) Fibroblasts were plated on 1.5mg/ml collagen matrices and stimulated with serum-free
media (SFM) or 4T1 conditioned media (CM) in the presence of control (c) or LOXL2-
specific (L) antibodies. Scale bar, 200μm. (B) Quantification of fibroblasts (fibs) alone or in
the presence of control (c) or LOXL2-specific antibody (L) invading through Matrigel (or
migrating through uncoated control membranes (C)) towards SFM or CM in the presence of
control or LOXL2-specific antibodies. ***P < 0.001. Scale bar, 500μm. (D) Contraction of
collagen matrices by fibroblasts after incubating in SFM or CM in the presence of control
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(c) or LOXL2-specific (L) antibodies over 96 hours. (E) Quantification of collagen
contraction seen in (D). **P < 0.01.
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Figure 3. Recombinant LOXL2 stimulates fibroblast branching on collagen, collagen contraction
and invasion of fibroblasts through ECM
(A) Fibroblasts were plated on 1.5mg/ml collagen matrices and stimulated with serum-free
media (SFM), TGFβ or recombinant LOXL2 (rLOXL2) protein. Scale bar, 200μm. (B)
Contraction of collagen matrices by fibroblasts after incubating in SFM, 4T1 conditioned
media (CM), TGFβ or rLOXL2 protein over 96 hours. (C) Quantification of collagen
contraction seen in (B). (D) Quantification of fibroblasts (fibs) invading through Matrigel
(or migrating through uncoated control membranes (E)) towards SFM or rLOXL2. **P <
0.01.
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Figure 4. Recombinant LOXL2 mediates fibroblast activation
(A) Western blot analysis of α-SMA expression in fibroblasts plated on collagen and
stimulated with 4T1 conditioned media (CM) in the presence of control (c) or LOXL2-
specific (L) antibodies or SFM in the presence of TGFβ or rLOXL2 protein. Fibroblasts
grown in SFM provided a control. Probing with an antibody to detect β-actin was used as a
loading control. (B) QRT-PCR analysis of acta2 mRNA expression in fibroblasts grown on
collagen in the presence of rLOXL2. Gene expression levels are shown as fold-changes over
the expression measured in fibroblasts grown in the presence of SFM alone. ***P < 0.001.
(C) Proliferation of fibroblasts grown over 3 days on top of collagen (or within collagen
(D)) in the presence of TGFβ or rLOXL2 protein assessed using an MTS assay. Proliferation
rates were compared with those of fibroblasts grown in SFM alone. *P < 0.05 and **P <
0.01. (E) QRT-PCR analysis of SDF1, FN and LOXL2 mRNA expression in fibroblasts
grown on collagen in the presence of rLOXL2 protein. Gene expression levels are shown as
fold-changes over the expression measured in fibroblasts grown in the presence of SFM
alone. **P < 0.01 and ***P < 0.001
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Figure 5. LOXL2-mediated matrix remodeling activates fibroblasts via FAK and Akt signaling
(A) Fibroblasts were plated on 1.5mg/ml collagen matrices and stimulated with serum-free
media (SFM), TGFβ or recombinant LOXL2 (rLOXL2) protein in the presence of control
(c) or blocking antibodies specific to β1 or β3 integrins (β1 Ab and β3 Ab, respectively).
Scale bar, 200μm. (B) Western blot analysis of α-SMA expression in fibroblasts plated on
collagen and stimulated with rLOXL2 in the presence of control antibody or blocking
antibodies specific to β1 or β3 integrins. Probing with an antibody to detect β-actin was used
as a loading control. (C) Western blot analysis of FAK activation (p-FAK) and Akt
activation (p-Akt) in fibroblasts plated on collagen and stimulated with rLOXL2 in the
presence of control antibody or blocking antibodies specific to β1 or β3 integrins.
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Expression of α-SMA was also determined. Probing with antibodies to detect total FAK,
Akt and β-actin were used as loading controls. (D) Western blot analysis of FAK activation
(p-FAK), Akt activation (p-Akt) and α-SMA expression in fibroblasts plated on collagen
and stimulated with rLOXL2 in the presence of SRC or FAK inhibitors (SRCI and FAKI,
respectively).
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